FIELD: medicine.
SUBSTANCE: present invention relates to a pharmaceutical composition for developing an antitumour immune response which contains at least one nucleic acid sequence, coding at least one specific neoantigen of the tumor cell, at least one viral particle of pox virus and CTLA4 antibody in an effective amount.
EFFECT: present invention provides developing an antitumour immune response.
13 cl
| Title | Year | Author | Number |
|---|---|---|---|
| M2-DEFECTIVE POXVIRUS | 2019 |
|
RU2819245C2 |
| PERSONALIZED VACCINE | 2018 |
|
RU2779987C2 |
| VACCINE COMPOSITION FOR TREATMENT OF CANCER | 2018 |
|
RU2782261C2 |
| ONCOLYTIC VIRUS FOR IMMUNOLOGIC CONTROL POINT MODULATORS EXPRESSION | 2015 |
|
RU2696312C2 |
| COMBINATION OF ONCOLYTIC VIRUS WITH MODULATORS OF IMMUNOLOGICAL CONTROL POINTS | 2015 |
|
RU2705780C2 |
| BIOMARKER FOR PATIENT'S MONITORING | 2010 |
|
RU2542435C2 |
| BIOMARKER FOR PATIENT MONITORING | 2010 |
|
RU2555340C2 |
| SOLUBLE ICAM-A AS BIOMARKER FOR PREDICTION OF THERAPEUTIC RESPONSE | 2010 |
|
RU2574984C2 |
| BIOMARKER FOR PATIENT SELECTION AND RELATED METHODS | 2010 |
|
RU2552292C2 |
| BIOMARKER FOR SELECTING PATIENTS AND RESPECTIVE QUESTIONS | 2009 |
|
RU2517719C2 |
